PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'European Commission, Joint Research Centre, Ispra, Italy.\', \'Instituto Gulbenkian de Ciência - Fundação Calouste Gulbenkian, Lisbon, Portugal.\', \'Physicians Committee for Responsible Medicine, Washington, DC, USA.\', \'Humane Society International, Washington, DC, USA.\', \'Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.\', \'Safer Medicines Trust, Kingsbridge, United Kingdom.\', \'U.S. Army Engineer Research and Development Center, Vicksburg, MS, USA.\', \'Organisation for Economic Co-operation and Development (OECD), Paris, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.14573/altex.2102221
?:doi
?:hasPublicationType
?:journal
  • ALTEX
is ?:pmid of
?:pmid
?:pmid
  • 33677612
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all